Abstract 28
Sequential infection with antigenically distinct influenza viruses induces cross-protective 29 immune responses against heterologous virus strains in animal models. Here we investigated 30 whether sequential immunization with antigenically distinct influenza vaccines can also 31 provide cross-protection. To this end, we compared immune responses and protective 32 potential against challenge with A(H1N1)pdm09 in mice infected sequentially with seasonal 33 A(H1N1) virus followed by A(H3N2) virus or immunized sequentially with whole inactivated 34 virus (WIV) or subunit (SU) vaccine derived from these viruses. Sequential infection provided 35 solid cross-protection against A(H1N1)pdm09 infection while sequential vaccination with WIV, 36 though not capable of preventing weight loss upon infection completely, protected the mice 37 from reaching the humane endpoint. In contrast, sequential SU vaccination did not prevent 38 rapid and extensive weight loss. Protection correlated with levels of cross-reactive but non-39 neutralizing antibodies of the IgG2a subclass, general increase of memory T cells and induction 40 of influenza-specific CD4+ and CD8+ T cells. Adoptive serum transfer experiments revealed 41 that despite lacking neutralizing activity, serum antibodies induced by sequential infection 42 protected mice from weight loss and vigorous virus growth in the lungs upon A(H1N1)pdm09 43 virus challenge. Antibodies induced by WIV vaccination alleviated symptoms but could not 44 control virus growth in the lung. Depletion of T cells prior to challenge revealed that CD8+ T 45 cells, but not CD4+ T cells, contributed to cross-protection. These results imply that sequential 46 immunization with WIV but not SU derived from antigenically distinct viruses could alleviate 47 the severity of infection caused by a pandemic and may improve protection to unpredictable 48 seasonal infection. 49 Importance Introduction 68 Influenza A virus (IAV) infections remain a worldwide public health threat. Influenza 69 vaccination is the most reliable strategy to control annual epidemics and irregular pandemics 70 [1] . Current inactivated influenza vaccines (IIV) primarily induce strain-specific antibodies 71 against the two major virus surface proteins, hemagglutinin (HA) and neuraminidase (NA). 72
However, these strain-specific antibodies cannot provide protection against antigenically 73 drifted and antigenically shifted strains. When a pandemic strain emerges, it takes around six 74 months to develop and distribute a new vaccine [2] , which is too late for a vaccine to provide 75 effective protection during the first pandemic wave. Thus, a cross-protective vaccine that 76 could provide immediate protection against unpredicted influenza virus strains is urgently 77
needed. 78
Live virus infection has been shown to provide some degree of cross-protection against [13] . Some anti-HA stalk antibodies can directly neutralize influenza virus 84 particles in vitro [14] . However, most of these antibodies target antigens that are expressed 85 on the surface of infected cells and then provide cross-protection via a Fc receptor dependent 86 mechanism[14][15] [16] . 87
Besides antibody responses, cross-reactive T cells induced by live virus infection have also 88
been demonstrated to correlate with cross-protection[6][17] [18] . Cytotoxic CD8 T cells can 89 recognize internal, conserved epitopes across different virus strains. In animal models, CD8 T 90 cells induced by live virus infection have been shown to prevent A(H5N1) or A(H1N1)pdm09 91 virus infection [19] . On the other hand, CD4 T cells specific for conserved epitopes have also 92 been shown to provide protection against A(H1N1)pdm09 in mice [20] Sequential immunization with antigenically distinct vaccines has also been used as a strategy 112 to induce a broader immune response against influenza virus in animal models [35] . However, 113 most of these studies were focused on the cross-protective immune response induced by 114 genetically modified vaccines [36] [37][38] [39] . Little is known about the protective potential 115 of sequential immunization with conventional inactivated vaccines derived from different 116 seasonal influenza virus strains. In case of a pandemic, such a vaccination strategy could be a 117 first means of intervention until a pandemic vaccine becomes available. 118
In this study, we assessed the cross-protective immune responses induced by sequential 119 infection with A(H1N1) and A(H3N2) virus, or sequential immunization with whole inactivated 120 virus (WIV) or subunit (SU) vaccine derived from these viruses in a mouse model. Sequential 121 infection provided robust cross-protection which was mediated by non-neutralizing, cross-122 reactive antibody and CD8 effector memory T cells (TEM). Partial cross-protection was 123 provided by sequential vaccination with WIV and was associated with CD8 central memory T 124 cells (TCM), and to a minor extent, with cross-reactive antibodies. In contrast, sequential 125 vaccination with SU vaccine induced low levels of cross-reactive serum antibodies and no T 126 cell immunity against A(H1N1)pdm09, and did not provide cross-protection. These results 127 imply that in case of a new pandemic, sequential immunization with WIV but not subunit 128 vaccines derived from different seasonal virus strains could mitigate disease severity until a 129 pandemic vaccine becomes available. 130
Materials and Methods

132
Virus and vaccines 133
Influenza virus strains A/Puerto Rico/8/34 (H1N1)(PR8), X-31, a reassortant virus derived from 134 A/Aichi/68 (H3N2), and A/California/07/2009 (H1N1)pdm09 were grown in embryonated 135 chicken eggs, and the virus preparations were titrated on MDCK cells and in mice. Whole 136 inactivated virus vaccines was produced from PR8, X31 and X-181 (HA and NA proteins from 137 A/California/7/2009 (H1N1)pdm09 and internal proteins from PR8) by treatment with β-138 propiolactone. PR8 subunit (SU) vaccine and X-31 SU were prepared from PR8 and X-31 WIV, 139 respectively, as described before [40] . 140
Vaccination, challenge and sample collection 141
Female 6-8 weeks old CB6F1 mice) were purchased from Envigo, The Netherlands, and rested 142 for at least one week. Mice were housed under SPF conditions in standard polycarbonate 143 cages (5 animals per cage) with standard rodent bedding and cardboard cylinders as cage 144 enrichment. Prior to the start of the experiment, animals were randomly allocated to the 145 different treatment groups. All animal experiments were approved by the Central Committee 146
for Animal Experiments CCD of the Netherlands (AVD105002016599). All experimental 147 protocols were approved by the Animal Ethics Committee of the University Medical Center 148
Groningen. Group sizes were determined using Piface software such that a power of at least 149 80% was reached. 150
Naive mice (n = 15) were immunized intramuscularly (i.m.) with 15 µg of PR8 WIV (containing 151 around 5 µg of HA) or 5 µg of PR8 SU vaccine. Alternatively, mice were anesthetized and 152 infected intranasally (i.n.) with a sublethal dose (10 3 TCID 50 ) of PR8 virus (live virus = LV). Four 153 weeks after immunization or infection, mice were i.m. immunized with 15 µg of X-31 WIV or 154 5 µg of X-31 SU or i.n. infected with a sublethal dose of (10 3 TCID 50 ) X-31 virus. Mice injected 155 twice with PBS i.m. with 28 days interval served as negative control (Table 1) On day 0 (before challenge) and day 3 post challenge, mice (n = 5 from each group) were 168 sacrificed under isoflurane anesthesia. Serum, nose wash and bronchoalveolar lavage (BAL) 169 were collected for further analysis. Lungs were perfused with 20 ml PBS containing 0.1% 170 heparin through the heart right ventricle. Right lung lobes were collected, homogenized, snap-171 frozen and stored at -80 o C for virus titration. The whole lung (day 0) or the left lung lobes (day 172
3) and the spleens were collected for lymphocyte isolation. 173
Viral titer in lung 174
Lung tissue collected on day 3 post-challenge was weighed, homogenized in 1 ml of Episerf 175 medium (Thermo Fisher Scientific) and then centrifuged at 1200 rpm for 10 minutes. 176
Supernatants were collected, aliquoted, snap-frozen and stored at -80 o C until use. Lung virus 177 titers were determined by infection of MDCK cells in 96-well plates with serial dilutions of the 178 lung supernatants as described before [40] . Viral titers, presented as log10 titer of 50% tissue 179 culture infectious dose per gram lung (log 10 TCID 50 /g), were calculated based on the Reed-180
Muench method [41] . 181
Isolation of lymphocytes from lung and spleen 182
Spleens were homogenized in complete IMDM (with 10% FBS, 1% Penicillin-Streptomycin and 183 0.1% β-mercaptoethanol) using a GentleMACS dissociator (Miltenyi Biotec B, Leiden, The 184 Netherlands). Cell suspensions were then forced through a cell strainer (BD Bioscience, Breda, 185
The Netherlands) and treated with ACK lysis buffer (0.15 M NH 4 Cl, 10 mM KHCO 3 , 0.1 mM 186 EDTA, pH 7.2) to remove erythrocytes. p8.91 and vector pCSFLW bearing the luciferase reporter were transfected alongside the 207 relevant HA glycoprotein genes in the plasmid pI.18 [43] . Parental PV were produced bearing 208 the HA of A/California/7/09 (H1), or A/duck/Memphis/546/1974 (H11). A chimeric HA (cHA) 209 consisting of the stalk from A/California/7/09 (H1) and head from A/duck/Memphis/546/1974 210 (H11) was also produced [44] . Pseudotype based microneutralisation assays (pMN) were 211 performed as described previously [43] . Briefly, serial dilutions of serum were incubated with 212 1x10 6 relative luminescence units (RLU) of HA bearing PV per well on a 96-well white plate for 213 1h at 37°C 5% CO 2 in a humidified incubator. 1.5x10 4 HEK293T/17 cells were then added per 214 well and plates incubated at 37°C 5% CO 2 for 48h before addition of Bright-Glo™ reagent Prism. Stalk-directed antibody presence was measured via antibody titers recorded against 217 the cHA and both of its parental strains (H11 and H1 PV). No (or negligible) antibodies should 218 be present against the exotic H11 HA, restricting neutralisation of the cHA PV to antibodies 219 directed against the conserved H1 stalk of the cHA. Control antibodies used included mAb 220 CR6261 (Crucell, Johnson and Johnson) and polyclonal antiserum Anti H11N9 (NIBSC). 221
Intracellular cytokine staining 222
For IFNγ intracellular cytokine staining, lymphocytes (1.5-2 x 10 6 ) from lung or spleen in 223 complete IMDM medium were stimulated with CD28 (1 µg/ml, eBioscience), with or without 224 X-181 WIV (10 µg/ml), overnight at 37 o C in a 5% CO 2 incubator. Protein transport inhibitor 225 cocktail (eBioscience) was added for the last 4 hours of stimulation. Stimulated cells were 226 stained with fluorochrome conjugated antibodies, including Alexa Fluor 700-antiCD3 (clone 227 17A2), FITC-antiCD4 (GK1.5), PerCP-cy5.5-antiCD8α (53-6.7), eFlour 450-antiCD62L (MEL-14), 228 APC-antiCD44 (IM7) for 45 minutes. After surface staining, cells were stained with Fixable 229
Viability Dye eFluor 780 (eBioscience) to identify dead cells. Cells were then fixed with IC 230 fixation buffer (eBioscience) and permeabilized with permeabilization buffer (eBioscience) 231 before intracellular staining with PE-cy7-antiIFNγ (clone XMG1.2) (all monoclonal antibodies 232 from eBioscience). Samples were acquired on a BD LSRII and data were analyzed by Kaluza® 233
Flow Cytometry Analysis Software. 234
ELISPOT and tetramer staining 235
Influenza NP-specific IFNγ-producing T cells were enumerated using a commercial mouse IFNγ 236
ELISpot kit (MABTEC, The Netherlands) according to the manufacturer's protocol. Briefly, 237 splenocytes (2.5 x 10 5 /well) collected on day 0 post-infection were incubated with or without 238 5 µg/ml of the PR8 NP 366-374 epitope (ASNENMDAM) in a pre-coated 96-well plate. After 239 overnight incubation, IFNγ-producing T cells were detected using alkaline phosphatase-240 conjugated anti-mouse IFNγ antibody. Spots were developed with BCIP/NBT substrate and 241 counted with an AID Elispot reader (Autoimmune Diagnostika GmbH, Strassberg, Germany). 242
The number of antigen-specific IFNγ-producing cells was calculated by subtracting the number 243 of spots detected in the unstimulated samples from the number in stimulated samples. 
CD4 and CD8 T cell depletion in vivo 258
For the T cell depletion study, mice were infected or vaccinated as described above and rested 259 for 28 days. Groups of mice (n = 6/group) were injected with anti-CD4 T cell depletion antibody 260 (200 µg/injection, GK1.5) or anti-CD8 T cell (200 µg/injection, YTS169). These antibodies were given i.p on day -1, 1 and 3 of A(H1N1)pdm09 virus (10 4.4 TCID 50 ) challenge. On day 6 post 262 challenge, lungs were collected for virus titration. Spleens were collected to confirm the 263 depletion of T cells. 264
Statistics 265
Mann-Whitney U test was used to determine the differences between read-outs of two 266 different groups. Statistical analyses were performed using GraphPad Prism version 6.01 for 267
Windows. GraphPad Sofware, La Jolla, California, USA www.graphpad.com. P < 0.05, 0.01, 268 0.001 were considered as significantly different and were denoted by *, **, ***, individually. 269
270
Results 271
Sequential infection, WIV and SU vaccination show different levels of cross-protective 272 capacity against H1N1pdm09 influenza virus infection 273
To investigate the cross-protective immune response induced by sequential infection or 274 vaccination with antigens from different influenza virus strains, we sequentially infected mice 275 with PR8 and X-31 influenza virus or sequentially vaccinated mice with WIV or SU vaccines 276 derived from these viruses. These viral strains were selected to reflect a heterosubtypic 277 exposure history in humans. The cross-protective capacity of sequential infection or 278 sequential immunization was determined by challenging the mice with virus 279
After A(H1N1)pdm09 virus challenge, mice in the sequential SU vaccination group showed 281 similar weight loss as mice in the PBS control group and developed severe symptoms, 282 necessitating euthanasia on day 6 or 7 post challenge ( Fig. 1 A, B) . Mice that were sequentially 283 vaccinated with WIV showed a similar trend of weight loss as mice in the PBS control group 284 until day 6 post infection. Yet, from day 7 post infection onwards, WIV immunized mice 285 recovered and none of the mice reached the humane endpoint. In the sequential infection 286 group, mice showed no or only minor weight loss after challenge and none of them needed to 287 be sacrificed. 288
On day 3 post-challenge, lung virus titers in the sequential SU vaccination group did not differ 289 significantly from those in the PBS control group (Fig. 1C ). In the sequential WIV vaccination 290 group, lung virus titers were decreased by 0.9 log 10 as compared to the PBS group (p = 0.03). 291
Sequential infection resulted in a significant decrease of the lung virus titer by 2 log 10 relative 292 to the control group (p = 0.015). 293
These data demonstrate that sequential immunization with WIV, although being less effective 294 than sequential infection with live virus, provided a certain level of cross-protection against 295 heterologous infection. In contrast, sequential SU vaccination did not provide cross-296 protection. 297
Sequential infection, WIV and SU vaccination induce distinct cross-reactive antibody 298 immune responses 299
To explore the immune mechanisms involved in protection from weight loss and lung virus 300 growth upon challenge, A(H1N1)pdm09 cross-reactive antibody responses induced by 301 sequential infection with PR8 and X-31 or immunization with PR8 and X-31 derived vaccines 302 were determined. 303
Sequential infection induced around 20 times more cross-reactive IgG antibody than 304 sequential WIV vaccination and approximately 75 times more cross-reactive IgG antibody than 305 sequential SU vaccination (p < 0.0001) ( Fig. 2A) . With respect to the subtype profile of the IgG 306 antibodies, sequential infection and WIV vaccination induced a Th1-type antibody response. 307
The average ratio of serum IgG2a to IgG1 concentration was 3 for mice sequentially infected 308 by live virus, compared with 1.5 induced by sequential WIV vaccination. In contrast, sequential 309 SU vaccination induced a similar amount of IgG1 antibody as induced by sequential WIV 310 vaccination but no IgG2a (Fig. 2B ). However, cross-reactive antibodies, irrespective of whether 311 induced by sequential infection or immunization, did not neutralize A(H1N1)pdm09 virus (Fig.  312   2C) . With respect to mucosal antibodies, only sequential infection was found to induce cross-313 reactive IgA antibody against A(H1N1)pdm09 virus in the nose (Fig. 2D) . 314
In order to reveal the target protein(s) of the observed cross-reactive antibodies we first 315 performed a pseudovirus-based assay to detect antibodies to the HA stalk domain. This assay 316 uses a chimeric HA as antigen, with an H11 globular head, and an H1 stalk. The chimeric HA 317 pseudovirus particles were effectively neutralized by the CR6261 mAb control which binds to 318 the H1 stalk. However, no antibodies reacting with the H1 stalk were observed in any of the 319 experimental groups (data not shown). Next, we examined anti-NA antibodies against 320 A(H1N1)pdm09 virus. The mice from the sequential infection group and 4 out of 5 mice from 321 the WIV vaccination group developed anti-NA antibodies, while only 2 out of 5 mice from the 322 sequential SU vaccination group did so and levels of anti-NA antibody were low (Fig. 3A) . Next, 323
anti-M2e antibody titers were determined by coating conserved M2e peptide onto 96-well 324 ELISA plate. Anti-M2e antibodies were only found in the sequential infection group (Fig. 3B) . 325
We also analyzed the presence of cross-reactive antibodies against conserved internal 326 proteins in serum using recombinant NP from HK68 (H3N2), which shows 90% of sequence 327 homology with NP from A(H1N1)pdm09. Sequential infection and WIV vaccination induced 328 similar though somewhat variable amounts of anti-NP antibodies (Fig. 3C ). As expected, no 329 anti-NP antibody was found in the sequential SU vaccination group. 330
These data indicate that sequential infection induced broader and higher amounts of cross-331 reactive non-neutralizing antibodies than sequential WIV vaccination, while SU vaccination 332 induced only antibodies against hemagglutinin and to a limited extent against neuraminidase. 333
Moreover, responses to live virus and WIV were dominated by IgG2a while responses to SU 334 consisted exclusively of IgG1 antibodies. 335
Sequential infection, WIV and SU vaccination induce different memory T cell immune 336 response 337
Apart from cross-reactive antibody response, cellular immune responses also play an 338 important role in cross-protection. We first evaluated the overall memory T cell responses in 339 spleen and lungs from mice after sequential infections or vaccinations. None of these 340 immunization strategies could significantly enhance the number of memory CD4+CD44+ T 341 cells (p = 0.28) (Fig. 4A ). However, numbers of memory CD8+CD44+ T cells were significantly 342 enhanced in spleen (p = 0.028) and lung (p = 0.015) of sequentially infected mice compared 343 with mice of the unvaccinated group (Fig. 4B) . Also, sequential WIV vaccination enhanced 344 memory CD8+CD44+ T cell numbers, however, only in spleen was significance reached (p = 345 0.02) (Fig. 4B) . No increase in the number of memory CD8 T cells was found in the sequential 346 SU vaccination group. Interestingly, while the CD8 memory T cell population in sequentially 347 infected mice consisted of CD62L negative TEM as well as CD62L positive TCM, the majority of 348 memory CD8 T cells from the sequential WIV vaccination group was CD62L positive (Fig. 4C) . 349
These data indicate that sequential infection and sequential immunization with WIV are 350 capable of stimulating CD8 memory responses while immunization with SU is not. 351
For detection of influenza specific T cells, splenocytes from sequentially infected or 352
sequentially immunized mice were stimulated overnight with WIV, and IFNγ production was 353 assessed by intracellular cytokine staining. In live virus infected mice, percentages of IFNγ 354 producing CD4+ and CD8+ memory T cells in spleen and lung were significantly higher than in 355 mock immunized mice (Fig. 5A,p < 0.05) . Moreover, around 90% of these IFNγ-producing CD8 356 T cells were effector memory cells (data not shown). Also in WIV immunized mice, enhanced 357 percentages of IFNγ positive CD4+ and CD8+ memory T cells were found, yet lower than in the 358 LV group. Significance as compared to PBS control animals was reached only for CD4+ T cells 359 in spleen. 360
The influenza-specific CD8 T cells induced by infection or immunization were also enumerated 361 by ELISPOT after stimulation of splenocytes with NP 366-374 peptide (ASNENMDAM) from PR8 362 virus (the epitope presents in PR8 as well as X-31 virus). NP-specific CD8 T cells were detected 363 in the WIV and the sequential infection group, but numbers were around 12 times higher in 364 the latter (Fig. 5B , p = 0.008). Next, we assessed the cross-reactivity of these NP-specific CD8 365 T cells to A(H1N1)pdm09 NP by staining with tetramers containing the ASENENMETM epitope 366 virus challenge (Fig. 6A) and lung virus titers in these animals were decreased by more than 2 380 logs compared to the titers in the PBS control group (Fig. 6B, p < 0.01) . Similarly, mice receiving 381 serum from the sequential infection group showed no or only mild weight loss. Interestingly, 382 despite the fact that the transferred serum did not contain any neutralizing antibodies, lung 383 virus titers in this group were decreased to the same low level as in mice which had received 384 serum from A(H1N1)pdm09-immunized mice containing neutralizing antibodies. Also serum 385 from the sequential WIV vaccination group provided partial protection; 4 out of 5 mice 386 receiving this serum showed no or mild weight loss, while one mouse went down quickly. Yet, 387 lung virus titers in the WIV vaccination group, though slightly lower, did not differ significantly 388 from those in PBS-treated controls (p = 0.22) (Fig. 6B) . 389
These data indicate that non-neutralizing antibodies induced by sequential infection were as 390 effective as neutralizing antibodies induced by A(H1N1)pdm09 WIV vaccination in providing 391 protection against A(H1N1)pdm09 virus challenge. However, non-neutralizing antibody 392 induced by sequential WIV vaccination were not sufficient to provide full cross-protection. 393
Memory T cells induced by sequential live virus infection or WIV vaccination are involved in 394
cross-protection against A(H1N1)pdm09 virus challenge 395
To determine the contribution of T cell immune responses to cross-protection against 396 A(H1N1)pdm09 virus infection, we used CD4 or CD8 specific antibodies to deplete T cells 397 before and during A(H1N1)pdm09 challenge. On day 6 post-challenge, we confirmed that 95% 398 of CD8 T cells or 96% of CD4 T cells in mice spleen were depleted by this treatment (data not 399 shown). 400
Mice in the PBS mock vaccination group, no matter whether treated with PBS, CD4 depletion 401 antibody or CD8 depletion antibody, showed continuous weight loss after A(H1N1)pdm09 402 challenge (Fig.6A, PBS) and displayed the same virus titers in lung tissue on day 6 post-403 infection (Fig. 6B, PBS) . In contrast, mice in the sequential infection group were protected 404 from weight loss and showed low or undetectable lung virus titers (Fig. 7A, LV) . Depletion of 405 CD4 T cells in these mice had no effect on protection. Depletion of CD8 T cells in the sequential 406 infection group had some effect on protection from weight loss; on day 6 post A(H1N1)pdm09 407 virus challenge 3 out of 6 mice had lost > 6.5 % weight while in non-depleted mice the most 408 severe weight loss was 2.1% and was observed in a single mouse only (Fig. 7A, LV) . In addition, 409 lung virus titers were about 1.5 log 10 higher in the CD8-depleted mice than in non-depleted 410 control mice of the sequential infection group; yet, virus titers were still significantly lower 411 than in non-immunized mice. In the WIV vaccination group, depletion of CD4 or CD8 T cell did 412 not significantly alter the weight loss compared with mock depletion but a strong trend 413 towards less weight loss was observed in mice depleted for CD4 T cells as compared to non-414 depleted mice of this group (P = 0.054, Fig. 7A, WIV) . Depletion of CD4 T cells decreased and 415 depletion of CD8 T cells increased lung virus titers by about 1 log as compared to non-depleted 416 animals on day 6 post challenge but these trends did not reach statistical significance (Fig. 7B,  417 WIV). Moreover, virus titers in WIV-immunized CD8 T cell-depleted mice were of the same 418 magnitude as those in the PBS mock vaccination group. 419
These data above suggests that CD4 memory T cells were most likely not involved in cross-420 protection while CD8 memory T cells induced by sequential infection or WIV immunization 421 contributed decisively to cross-protection.
Discussion 423
To determine whether sequential immunization with antigenically distinct traditional vaccines 424 could provide cross-protection, mice were sequentially immunized with WIV or SU vaccines 425 derived from PR8 and X-31 viruses and then challenged with an A(H1N1)pdm09 virus. Another 426 group of mice was sequentially infected with sublethal doses of PR8 followed by X-31 prior to 427 A(H1N1)pdm09 virus challenge. We demonstrate that sequential infection provided solid 428 cross-protection which was correlated with cross-protective antibodies and CD8 TEM cells. 429
Sequential vaccination with WIV provided partial cross-protection which also correlated with 430 induction of cross-reactive antibodies and CD8 T cells. Yet, sequential SU vaccination did not 431 provide cross-protection. 432
Neither sequential infection nor sequential immunization resulted in induction of antibodies 433 capable of neutralizing A(H1N1)pdm09 virus. Yet, substantial amounts of cross-reactive non-434 neutralizing antibodies were induced. Previous publications have shown that non-neutralizing 435 antibodies, for example anti-HA stem antibodies, can be induced by sequential infection with 436 antigenically distinct viruses and may provide cross-protection against A(H1N1)pdm09 437 influenza virus infection[11] [12] . In contrast to these findings, no anti-HA stem antibodies 438 were found in this study. This may be due to the fact that the two virus strains (PR8 and X-31) 439 used for infection/immunization belong to two different phylogenetic groups. The HA-stem 440 regions from PR8 and X-31 virus show low similarity, which might have impaired boosting of 441 HA-stem reactive B cells induced by PR8 through exposure to X-31. Nevertheless, we found 442 cross-reactive antibodies against other conserved proteins in this study. Anti-M2e, anti-NP 443 and anti-NA antibodies were induced by sequential infection and, although to a lesser extent, 444 by sequential WIV immunization. In contrast, sequential SU immunization induced only very 445 moderate amounts of anti-NA antibodies cross-reactive with A(H1N1)pdm09 virus.
Since no neutralizing antibodies were found, the cross-reactive but non-neutralizing 447 antibodies likely are the reason for the cross-protection observed in the serum adoptive 448 transfer experiment. Non-neutralizing antibodies can provide cross-protection via Fc receptor 449 dependent mechanisms (reviewed in [45] ). Interestingly, control of lung virus growth by non-450 neutralizing antibodies evoked by sequential infection with PR8 and X-31 was as effective as 451 by neutralizing antibodies evoked by A(H1N1)pdm09 WIV. Even in absence of antigen-specific 452 T cells, neutralizing antibodies are thus not crucial for protection, suggesting that non-453 neutralizing antibodies maybe more important for cross-protection than generally thought. 454
Interestingly, recent studies revealed that in humans antibodies cross-reacting with different 455 influenza virus strains are common and that these antibodies are effectively enhanced by These 460 studies imply that the amount of non-neutralizing cross-reactive antibodies may also play an 461 important role in cross-protection. In the present study, cross-reactive antibody titers evoked 462 by sequential WIV immunization were 20-fold lower than those evoked by sequential infection. 463
We thus speculate that antibodies induced by WIV immunization, though in principle cross-464 protective as indicated by our data, were not present in sufficient amounts to confer complete 465
protection. 466
Although sequential infection and sequential WIV immunization induced virus-specific IFNγ-467 producing CD4 T cells, depletion of CD4 T cells in this study did not influence the cross-468 protection, neither in the sequential infection group nor in the sequential WIV vaccination group. These results contrast with previous findings which indicate that CD4 T cells might play 
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